Repligen outlines strategy to drive mid-teens revenue CAGR through 2030, targets ~30% adjusted EBITDA margin - RGEN News | RalliesRepligen outlines strategy to drive mid-teens revenue CAGR through 2030, targets ~30% adjusted EBITDA margin
R
RGEN• China and acquisition updates
- China strategy highlighted an OEM manufacturing agreement; China revenue rose 60% in 1H-26.
- BioLife acquisition positioned as a catalyst to expand capabilities and build on momentum in bioprocessing.
Strategy and medium-term financial targets
- Repligen presented at the Wells Fargo 21st Annual Healthcare Conference, outlining strategy to outpace bioprocessing market growth.
- FY25 revenue of USD 738 million; medium-term model targets a mid-teens revenue CAGR through 2030, assuming modest M&A.
- Margin plan targets about 30% adjusted EBITDA margin, alongside a “fit for growth” transformation program.
•
